ABL Bio Inc. (KOSDAQ:298380)
South Korea · Delayed Price · Currency is KRW 71,000
-1,700 (-2.34%)
Sep 1, 2026, 3:30 PM KST
ABL Bio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 34,283 | 79,350 | 33,403 | 65,547 | 67,301 | 5,332 |
Other Revenue | -0 | -0 | -0 | 0 | -0 | 0 |
| 34,283 | 79,350 | 33,403 | 65,547 | 67,301 | 5,332 | |
Revenue Growth | -63.89% | 137.55% | -49.04% | -2.61% | 1162.19% | - |
Cost of Revenue | 114.68 | 120.84 | 61.26 | 46.25 | 83.76 | 47.98 |
Gross Profit | 34,168 | 79,229 | 33,342 | 65,501 | 67,217 | 5,284 |
Selling, General & Admin | 28,099 | 23,156 | 16,231 | 13,493 | 15,569 | 13,962 |
Research & Development | 88,258 | 93,014 | 74,079 | 52,035 | 48,416 | 41,034 |
Operating Expenses | 120,288 | 119,619 | 92,719 | 68,118 | 66,309 | 56,472 |
Operating Income | -86,119 | -40,390 | -59,377 | -2,617 | 908 | -51,188 |
Interest Expense | -1,602 | -993.05 | -36.04 | -2,151 | -1,326 | -41.98 |
Interest & Investment Income | 3,356 | 2,978 | 1,877 | 1,294 | 233.75 | 99.72 |
Currency Exchange Gain (Loss) | 5,370 | 604.86 | 1,373 | 734.04 | 1,761 | 864.43 |
Other Non Operating Income (Expenses) | -580.83 | -453.09 | 249.56 | -1,037 | 2,176 | 47.62 |
EBT Excluding Unusual Items | -79,575 | -38,254 | -55,914 | -3,776 | 3,753 | -50,218 |
Gain (Loss) on Sale of Investments | 415.19 | 384.69 | 391.27 | 1,132 | -592.13 | 6,666 |
Gain (Loss) on Sale of Assets | -8.52 | -8.52 | -7.03 | -2.64 | 48 | -5.83 |
Pretax Income | -79,169 | -37,877 | -55,529 | -2,647 | 3,209 | -43,558 |
Earnings From Continuing Operations | -79,169 | -37,877 | -55,529 | -2,647 | 3,209 | -43,558 |
Minority Interest in Earnings | 537.65 | 71 | - | - | - | - |
Net Income | -78,631 | -37,806 | -55,529 | -2,647 | 3,209 | -43,558 |
Net Income to Common | -78,631 | -37,806 | -55,529 | -2,647 | 3,209 | -43,558 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 55 | 52 | 48 | 48 | 48 | 47 |
Shares Outstanding (Diluted) | 55 | 52 | 48 | 48 | 48 | 47 |
Shares Change | 14.30% | 7.25% | 0.37% | 0.58% | 1.27% | - |
EPS (Basic) | -1424.72 | -734.08 | -1156.34 | -55.32 | 67.46 | -927.36 |
EPS (Diluted) | -1424.72 | -734.08 | -1156.34 | -55.32 | 67.46 | -927.36 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -47,083 | -61,318 | -78,426 | -34,102 | 70,076 | -41,850 |
Free Cash Flow Per Share | -853.10 | -1190.60 | -1633.14 | -712.77 | 1473.23 | -890.99 |
Gross Margin | 99.67% | 99.85% | 99.82% | 99.93% | 99.88% | 99.10% |
Operating Margin | -251.20% | -50.90% | -177.76% | -3.99% | 1.35% | -959.99% |
Profit Margin | -229.36% | -47.64% | -166.24% | -4.04% | 4.77% | -816.91% |
Free Cash Flow Margin | -137.34% | -77.28% | -234.79% | -52.03% | 104.12% | -784.87% |
EBITDA | -82,189 | -36,941 | -56,967 | -27.32 | 3,233 | -49,029 |
EBITDA Margin | -239.74% | -46.55% | -170.55% | -0.04% | 4.80% | - |
D&A For EBITDA | 3,930 | 3,449 | 2,410 | 2,590 | 2,325 | 2,158 |
EBIT | -86,119 | -40,390 | -59,377 | -2,617 | 908 | -51,188 |
EBIT Margin | -251.20% | -50.90% | -177.76% | -3.99% | 1.35% | - |